Orchid Pharma Ltd. - Research Center
524372 ORCHIDPHAR Group (Z) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 40.82 | 88.96 | 88.96 | 88.96 | 88.96 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 1,015.38 | -843.95 | -763.10 | -431.88 | 82.17 |
| Loan funds | |||||
| Secured loans | 501.47 | 2,120.10 | 2,588.20 | 2,756.30 | 2,872.29 |
| Unsecured loans | - | - | - | - | 138.87 |
| Total | 1,557.67 | 1,365.11 | 1,914.07 | 2,413.39 | 3,182.30 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 1,419.94 | 1,419.36 | 1,558.11 | 1,538.24 | 2,807.19 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 381.13 | 258.01 | 266.83 | 136.53 | 1,266.83 |
| Net block | 1,038.81 | 1,161.35 | 1,291.28 | 1,401.71 | 1,540.36 |
| Capital work-in-progress | 88.52 | 278.16 | 271.53 | 288.31 | 280.40 |
| Investments | 0.34 | 0.47 | 124.77 | 124.84 | 124.65 |
| Net current assets | |||||
| Current assets, loans & advances | 584.07 | 1,553.28 | 1,523.19 | 1,543.49 | 2,017.12 |
| Less : current liabilities & provisions | 154.07 | 1,628.15 | 1,296.70 | 944.95 | 780.23 |
| Total net current assets | 430.00 | -74.87 | 226.49 | 598.54 | 1,236.88 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 1,557.67 | 1,365.11 | 1,914.07 | 2,413.39 | 3,182.30 |
| Notes: | |||||
| Book value of unquoted investments | 125.04 | 125.04 | 125.04 | 125.04 | 124.56 |
| Market value of quoted investments | 0.06 | 0.19 | 0.19 | 0.26 | 0.17 |
| Contingent liabilities | 0.97 | 143.87 | 178.39 | 194.78 | 248.25 |
| Number of equity sharesoutstanding (Lacs) | 408.16 | 889.64 | 889.64 | 889.64 | 889.64 |
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis